AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10498759 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil capsules (2 g b.d.; placebo group)
Number of subjects: 49
Study 10498759 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplements (self-reported use)
Number of subjects: 49
Study 10498759 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 49
Study 8604261 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-norepinephrine topical solution (Bupivanor)
Number of subjects: 240
Study 8604261 — intervention group
Group type: COMPARATOR
Intervention: Topical tetracaine-adrenaline-cocaine (TAC)
Number of subjects: 240
Study 8604261 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine infiltration
Number of subjects: 240
Study 1934591 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms rIFN-gamma
Number of subjects: 5
Study 1934591 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms rIFN-gamma
Number of subjects: 5
Study 1934591 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-2-microglobulin
Number of subjects: 5
Study 7051998 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mastectomy and axillary node sampling with selective radiotherapy
Number of subjects: 0
Study 7051998 — intervention group
Group type: COMPARATOR
Intervention: Patey mastectomy
Number of subjects: 0
Study 30689402 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus everolimus
Number of subjects: 0
Study 30689402 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 0
Study 30689402 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib monotherapy
Number of subjects: 0
Study 28166116 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic treadmill exercise
Number of subjects: 11
Study 28166116 — intervention group
Group type: COMPARATOR
Intervention: Land-based treadmill exercise
Number of subjects: 11
Study 27393796 — intervention group
Group type: EXPERIMENTAL
Intervention: New integrated educational model
Number of subjects: 64
Study 27393796 — intervention group
Group type: COMPARATOR
Intervention: Standard group (control)
Number of subjects: 64
Study 24398222 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (8-week home-based program)
Number of subjects: 384
Study 24398222 — intervention group
Group type: COMPARATOR
Intervention: Bracing (semirigid ankle brace worn during all sports activities for 12 months)
Number of subjects: 384
Study 24398222 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bracing and neuromuscular training (8 weeks of training and brace during all sports activities)
Number of subjects: 384
Study 21391283 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 12
Study 21391283 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 12
Study 21391283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19132412 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 283
Study 19132412 — intervention group
Group type: COMPARATOR
Intervention: Prolonged conservative care
Number of subjects: 283
Study 17257413 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal revascularization
Number of subjects: 0
Study 17257413 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study 15050319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated accelerated radiochemotherapy (to 70.6 Gy) with concurrent mitomycin C and 5-fluorouracil
Number of subjects: 83
Study 15050319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated accelerated radiotherapy (RT) alone (to a total radiation dose of 77.6 Gy)
Number of subjects: 83
Study 15050319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated accelerated radiochemotherapy (to 70.6 Gy)
Number of subjects: 83
Study 15050319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated accelerated radiochemotherapy
Number of subjects: 83
Study 15050319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated accelerated RT alone
Number of subjects: 83
Study 15448032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (3 or 10 mg/kg every 2 weeks)
Number of subjects: 0
Study 15448032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (higher dose)
Number of subjects: 0
Study 15448032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (long-term therapy)
Number of subjects: 0
Study 15448032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and thalidomide (pilot trial)
Number of subjects: 0
Study 10353887 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte‐monocyte colony‐stimulating factor (GM‐CSF; 250 microg/m2/day for 5 days)
Number of subjects: 30
Study 8557014 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 20 micrograms kg‐1 and propofol 2.0‐2.5 mg kg‐1
Number of subjects: 40
Study 8557014 — intervention group
Group type: COMPARATOR
Intervention: fentanyl 3 micrograms kg‐1 and thiopentone 4‐6 mg kg‐1
Number of subjects: 40
Study 1660414 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone treatment in steroid‐treated control group (n = 10)
Number of subjects: 15
Study 1660414 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atopic dermatitis (AD)
Number of subjects: 15
Study 1660414 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone treatment
Number of subjects: 15
Study 6627819 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (100 to 400 mg/day) with prazosin (2 to 4 mg/day)
Number of subjects: 20
Study 6627819 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol (200 to 1000 mg/day)
Number of subjects: 20
Study 6627819 — intervention group
Group type: COMPARATOR
Intervention: metoprolol with or without prazosin
Number of subjects: 20
Study 6627819 — intervention group
Group type: COMPARATOR
Intervention: labetalol
Number of subjects: 20
Study 31812550 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 38
Study 31812550 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 38
Study 31812550 — intervention group
Group type: COMPARATOR
Intervention: Control (untrained)
Number of subjects: 38
Study 31728883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy of 39 Gy in 13 fractions over 2.6 weeks with concurrent Temozolomide (TMZ) 75 mg/m2 from day 1 to day 17 followed by adjuvant TMZ for six cycles.
Number of subjects: 35
Study 31728883 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy of 60 Gy in 30 fractions over 6 weeks.
Number of subjects: 35
Study 30171076 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 30
Study 30171076 — intervention group
Group type: COMPARATOR
Intervention: Nonrobotic physiotherapy (nR-PT)
Number of subjects: 30
Study 27362944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) in nonvitrectomized eyes
Number of subjects: 25
Study 27362944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) in vitrectomized eyes
Number of subjects: 25
Study 27362944 — intervention group
Group type: COMPARATOR
Intervention: Comparison between nonvitrectomized and vitrectomized groups
Number of subjects: 25
Study 25247320 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling
Number of subjects: 6000
Study 25247320 — intervention group
Group type: COMPARATOR
Intervention: Recall
Number of subjects: 6000
Study 25247320 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 6000
Study 22770926 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (three 140‐mg tablets daily for 3 months)
Number of subjects: 60
Study 22770926 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 tablets daily for 3 months)
Number of subjects: 60
Study 22770926 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 60
Study 20398339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artesunate (2.4 mg/kg immediately followed by 1.2 mg/kg at 12 hours then 24 hours then daily)
Number of subjects: 370
Study 20398339 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular artemether (3.6 mg/kg immediately followed by 1.8 mg/kg daily)
Number of subjects: 370
Study 17512087 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 3x/week for 4 weeks (course 1)
Number of subjects: 0
Study 17512087 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 3x/week for 4 weeks (course 1) and another course for remaining lesions
Number of subjects: 0
Study 17512087 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod 5% cream
Number of subjects: 0
Study 17512087 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 0
Study 16276328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative I‐O at the start of weaning
Number of subjects: 301
Study 16276328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative I‐O at extubation
Number of subjects: 301
Study 12188448 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinacrine pellets insertion with TVS after standing up promptly
Number of subjects: 20
Study 12188448 — intervention group
Group type: COMPARATOR
Intervention: Quinacrine pellets insertion with TVS after lying down for 30 minutes
Number of subjects: 20
Study 9726388 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 12
Study 9726388 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 12
Study 9726388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7653830 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg i.v.
Number of subjects: 80
Study 7653830 — intervention group
Group type: COMPARATOR
Intervention: droperidol 2.5 mg i.v.
Number of subjects: 80
Study 2720018 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam, Alprazolam, or Placebo (8-week trial)
Number of subjects: 120
Study 2720018 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 120
Study 2720018 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone Suppression Test (DST)
Number of subjects: 120
Study 2720018 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (Diazepam, Alprazolam)
Number of subjects: 120
Study 789024 — intervention group
Group type: EXPERIMENTAL
Intervention: Th1165a (5 mg)
Number of subjects: 10
Study 789024 — intervention group
Group type: EXPERIMENTAL
Intervention: Th1165a (10 mg)
Number of subjects: 10
Study 789024 — intervention group
Group type: EXPERIMENTAL
Intervention: Th1165a (15 mg)
Number of subjects: 10
Study 789024 — intervention group
Group type: EXPERIMENTAL
Intervention: Th1165a (20 mg)
Number of subjects: 10
Study 789024 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol sulfate (20 mg)
Number of subjects: 10
Study 789024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30556110 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 15 mg
Number of subjects: 11264
Study 30556110 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 400 mg
Number of subjects: 11264
Study 30556110 — intervention group
Group type: COMPARATOR
Intervention: Acalabrutinib 100 mg
Number of subjects: 11264
Study 30556110 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP-5862
Number of subjects: 11264
Study 30556110 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 11264
Study 28873161 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy outreach (n=2400)
Number of subjects: 5999
Study 28873161 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT outreach (n=2400)
Number of subjects: 5999
Study 28873161 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=1199)
Number of subjects: 5999
Study 28873161 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy outreach vs FIT outreach
Number of subjects: 5999
Study 28873161 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy outreach
Number of subjects: 5999
Study 28873161 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT outreach
Number of subjects: 5999
Study 25155034 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily (OaD)
Number of subjects: 423
Study 25155034 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg on demand (PRN)
Number of subjects: 423
Study 25155034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 23827533 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualised Individual Cognitive Behaviour Treatment (M‐iCBT)
Number of subjects: 32
Study 23827533 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 32
Study 21272272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) for up to 6 months
Number of subjects: 288
Study 21272272 — intervention group
Group type: COMPARATOR
Intervention: Frequent mental-state monitoring
Number of subjects: 288
Study 19623415 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebodium Decumanum
Number of subjects: 24
Study 19623415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 24
Study 16827021 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine grit straight fissure diamond bur in air rotor (DA)
Number of subjects: 60
Study 16827021 — intervention group
Group type: EXPERIMENTAL
Intervention: Crosscut fissure carbide bur in air rotor (CCA)
Number of subjects: 60
Study 16827021 — intervention group
Group type: EXPERIMENTAL
Intervention: Crosscut fissure carbide bur in micromotor (CCM)
Number of subjects: 60
Study 16827021 — intervention group
Group type: COMPARATOR
Intervention: Plain fissure carbide bur in micromotor (CM)
Number of subjects: 60
Study 16827021 — intervention group
Group type: COMPARATOR
Intervention: #600-grit silicon carbide paper (SiC)
Number of subjects: 60
Study 14677177 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-manufactured rigid carbon graphite foot orthoses (RA-orthosis)
Number of subjects: 0
Study 14677177 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no orthotic intervention (RA-control)
Number of subjects: 0
Study 10767671 — intervention group
Group type: EXPERIMENTAL
Intervention: Active capsules containing 160 mg of bilberry extract (25-percent anthocyanosides) taken three times daily for 21 days
Number of subjects: 15
Study 10767671 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules containing only inactive ingredients taken three times daily for 21 days
Number of subjects: 15
Study 9496202 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg orally, given daily for 5 days before operation
Number of subjects: 29
Study 9496202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9496202 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 29
Study 7938796 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite extract (HDM)
Number of subjects: 20
Study 3332506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (250 mg) and sulfadoxine‐pyrimethamine once a week
Number of subjects: 338
Study 3332506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (two tablets) once a week
Number of subjects: 338
Study 3332506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (one tablet containing sulfadoxine 500 mg and pyrimethamine 25 mg) twice a week
Number of subjects: 338
Study 30286363 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniArc
Number of subjects: 246
Study 30286363 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT Abbrevo
Number of subjects: 246
Study 28019134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers carrying boys
Number of subjects: 74
Study 28019134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers carrying girls
Number of subjects: 74
Study 27703984 — intervention group
Group type: EXPERIMENTAL
Intervention: Effitix (permethrin 6.1% and fipronil 54.5%)
Number of subjects: 182
Study 27703984 — intervention group
Group type: COMPARATOR
Intervention: Advantix (permethrin and imidacloprid combination)
Number of subjects: 182
Study 23870287 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. every 4 weeks (Q4W)
Number of subjects: 30
Study 23870287 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. every 2 weeks (Q2W)
Number of subjects: 30
Study 23870287 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa every 4 weeks (Q4W)
Number of subjects: 30
Study 23870287 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa every 2 weeks (Q2W)
Number of subjects: 30
Study 23870287 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. (any administration interval)
Number of subjects: 30
Study 23870287 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortening administration interval (Q2W)
Number of subjects: 30
Study 21986645 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro-gastric sutures (group A, n=41)
Number of subjects: 81
Study 21986645 — intervention group
Group type: COMPARATOR
Intervention: Non-fixation (group B, n=40)
Number of subjects: 81
Study 21986645 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro-gastric sutures (group A)
Number of subjects: 81
Study 21986645 — intervention group
Group type: COMPARATOR
Intervention: Non-fixation (group B)
Number of subjects: 81
Study 21986645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study 19276275 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly targeted agents
Number of subjects: 0
Study 19276275 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized phase II designs
Number of subjects: 0
Study 19276275 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 0
Study 16428565 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation using the ReliefBand at the P6 point
Number of subjects: 94
Study 14624295 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum isometric strength
Number of subjects: 40
Study 14624295 — intervention group
Group type: EXPERIMENTAL
Intervention: Body size (expressed as fat-free body mass)
Number of subjects: 40
Study 14624295 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength
Number of subjects: 40
Study 11413177 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 1872
Study 11413177 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 1872
Study 11413177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitrates
Number of subjects: 1872
Study 11413177 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin, aspirin, beta blockers, intravenous nitrates
Number of subjects: 1872
Study 11413177 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 1872
Study 11413177 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, aspirin and heparin, coronary angiography
Number of subjects: 1872
Study 11413177 — intervention group
Group type: EXPERIMENTAL
Intervention: Most interventions
Number of subjects: 1872
Study 9163261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 2 mg/kg body weight i.v. 20 min before surgery
Number of subjects: 48
Study 9163261 — intervention group
Group type: COMPARATOR
Intervention: Placebo i.v. at the end of surgery
Number of subjects: 48
Study 8431344 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 4 micrograms kg‐1
Number of subjects: 10
Study 8431344 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 10
Study 3108429 — intervention group
Group type: EXPERIMENTAL
Intervention: LYN-EE (750 micrograms lynestrenol and 37.5 micrograms ethinyl estradiol)
Number of subjects: 50
Study 3108429 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-EE (150 micrograms levonorgestrel and 30 micrograms ethinyl estradiol)
Number of subjects: 50
Study 3108429 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 matched subjects)
Number of subjects: 50
Study 28881462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) 80 mg every 4 weeks (Q4W) or every 2 weeks (Q2W) after an initial 160 mg dose
Number of subjects: 1133
Study 28881462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) Q2W
Number of subjects: 1133
Study 28881462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 1133
Study 28881462 — intervention group
Group type: COMPARATOR
Intervention: Ixekizumab (IXE) or Etanercept (ETN)
Number of subjects: 1133
Study 28881462 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (ETN; 50 mg twice weekly)
Number of subjects: 1133
Study 28881462 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1133
Study 26742907 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (65 mg/cup espresso)
Number of subjects: 76
Study 26742907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (espresso without caffeine)
Number of subjects: 76
Study 25118076 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-Minute Walking Test (6MWT)
Number of subjects: 296
Study 22040841 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 40
Study 20413278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoic acid (E-EPA)
Number of subjects: 0
Study 20413278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18482245 — intervention group
Group type: COMPARATOR
Intervention: Propofol (3.5 mg.kg(‐1))
Number of subjects: 60
Study 18482245 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-Ketamine (2.5 mg.kg(‐1))
Number of subjects: 60
Study 18482245 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-Midazolam (2.5 mg.kg(‐1))
Number of subjects: 60
Study 15998172 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 0
Study 15998172 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol combination
Number of subjects: 0
Study 12926840 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology treatment (manual pressure on specific points in the feet and massage of the calf area)
Number of subjects: 71